News for Beam Therapeutics Inc. (BEAM)

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. ( BEAM), a biotechnology company developing precision genetic medicines through ba

**media[561632]**

ARK Invest bolstered its stake in Beam Therapeutics (BEAM) with 170,778 shares on February 20, 2025, owning nearly 7.7 million shares or 8.54% of the company, despite a 31% year-over-year drop. Scotiabank raised Beam’s price target to $25 from $24 with a 'Sector Perform' rating, showing cautious optimism, while short-seller…

Cathie Wood is back in the spotlight, and so is her flagship ARK Innovation ETF (NYSE:ARKK). After a rough year, the fund is showing signs of life—but is this the start of a real comeback, or just another short-lived rally? Investors are split, and the numbers tell an interesting story. ARKK's Rebound, Skeptics, and the High-Stakes Bet on Innovation So far this year, ARKK is up 6%—a solid lead over the S&P 500's 2% gain and the Nasdaq's 1% increase. That's a welcome shift after 2024, when ARKK r

Beam Therapeutics Inc (BEAM) showcases a robust base editing technology platform with promising product candidates like BEAM-101 and BEAM-302.Despite significa

BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

Revenue: $30.07 million for Q4 2024, surpassing the estimated $16.93 million.Earnings Per Share (EPS): Reported at -$1.09, beating the estimated -$1.18.Cash Po

Beam Therapeutics Inc (BEAM), a biotechnology company specializing in precision genetic medicines, announced its fourth quarter and full year 2024 financial res

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of 0.91% and 44.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025

Summary Beam Therapeutics Inc (BEAM), a biotechnology company specializing in precision genetic medicines through base editing, announced on February 24, 2025,

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. ( BEAM), a biotechnology company developing precision genetic medicines through bas

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Beam Therapeutics Inc.

On Friday, Cathie Wood-led Ark Invest made significant trades involving Beam Therapeutics Inc. BEAM, Nu Holdings Ltd. NU, MercadoLibre Inc. MELI, and Adaptive B...

Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA.

U.S. stocks were mostly lower, with the Dow Jones falling around 100 points on Friday. Shares of The Goodyear Tire & Rubber Company GT rose sharply during Frid...

The average of price targets set by Wall Street analysts indicates a potential upside of 67.3% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

On December 31, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, executed a significant transaction involving Beam Therapeutics Inc (BEAM). The f

Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.